β-Funaltrexamine is protective against LPS-induced CXCL10 expression and behavioral impairments

Keyphrases

• CXCL10 100%
• Lipopolysaccharide-induced 100%
• Behavioral Impairment 100%
• Inflammation 75%
• Lipopolysaccharide 50%
• Neuroinflammation 50%
• Whole Brain 50%
• Sickness 50%
• Liver 25%
• Alzheimer's Disease 25%
• Brain Regions 25%
• Brainstem 25%
• Cerebellum 25%
• Chemokine Expression 25%
• IP-10 25%
• Interferon-inducible Protein 10 25%
• Spleen 25%
• Therapeutic Potential 25%
• Astroglial Cells 25%
• Parkinson's Disease 25%
• Inflammatory Pathways 25%
• Neuroprotective Effect 25%
• Open Field Test 25%
• Anti-inflammatory Effect 25%
• Anxiety-like Behavior 25%
• C57BL 25%
• Enzyme-linked Immunosorbent Assay (ELISA) 25%
• Neurological Disorders 25%
• NF-B 25%
• Mu-opioid Receptor Antagonist 25%
• Differential Effects 25%
• Peripheral Inflammation 25%
• Prefrontal Cortex 25%
• Potential Therapeutics 25%
• Inflammatory Chemokines 25%
• Small Intestine 25%
• Elevated Plus Maze 25%
• Inflammatory Bowel Disease 25%
• Female Mice 25%
• Pharmacological Agents 25%
• Peripheral System 25%
• Large Intestine 25%
• Potential Treatments 25%
• Brain Hippocampus 25%
• Stress-induced Depression 25%
• Central System 25%
• Treatment Development 25%
• Continuation Treatment 25%

Neuroscience

• Lipopolysaccharide 100%
• CXCL10 100%
• Behavior (Neuroscience) 50%
• Chemokine 33%
• Alzheimer's Disease 16%
• Brainstem 16%
• Cerebellum 16%
• In Vitro 16%
• Gamma Interferon Inducible Protein 10 16%
• Hippocampus 16%
• Parkinson's Disease 16%
• Neuroprotective Agent 16%
• Anti-Inflammatory 16%
• μ-Opioid Receptor 16%
• Prefrontal Cortex 16%
• Neurological Disorder 16%
• Elevated Plus Maze 16%
• Inflammatory Bowel Disease 16%
• Interferon Gamma 16%
• Treatment Development 16%
• Narcotic Antagonist 16%
• Blood Plasma 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Lipopolysaccharide 100%
• Disease 80%
• Inflammation 80%
• Chemokine 40%
• Alzheimer's Disease 20%
• Antiinflammatory Activity 20%
• Gamma Interferon Inducible Protein 10 20%
• Mu Opiate Receptor Antagonist 20%
• Enzyme-Linked Immunosorbent Assay 20%
• Neuroprotective Agent 20%
• Neurologic Disease 20%
• Preclinical Study 20%
• Parkinson's Disease 20%
• Inflammatory Bowel Disease 20%
• Gamma Interferon 20%
• Lipopolysaccharide-Induced Neuroinflammation 20%